Organ transplant recipients currently face frequent biopsies to monitor for problems like graft injury or rejection, and doctors don't have a good way of differentiating between rejection and other causes of dysfunction. A new blood test is now available, however, that is designed to address both issues for kidney transplant recipients.

Medtronic (Dublin) seems determined to climb back up on the renal denervation horse. The company has kicked off a new clinical feasibility study that will combine pulmonary vein isolation (PVI) and renal denervation for the treatment of paroxysmal or persistent atrial fibrillation (AF), compared to PVI alone.